Bionomics (BNO.AX) Osake Kurssi

Bionomics Ltd is primarily active in the biotechnology and pharmaceutical industries.

Bionomics Ltd faces strong competition in the market from pharmaceutical companies such as Novartis, Pfizer, and GlaxoSmithKline. These industry giants also focus on developing innovative drug therapies and discovering potential treatments. Bionomics Ltd's main competitors continually invest in research and development, similar to Bionomics Ltd, to stay competitive in the healthcare industry. As a biotech company, Bionomics Ltd aims to deliver groundbreaking solutions that cater to unmet medical needs. With these key players in the market, Bionomics Ltd strives to differentiate itself through its unique approaches and effective drug development strategies.

Bionomics Ltd is a biotechnology company based in Australia. Founded in 1999, it specializes in the discovery and development of innovative therapeutics for various diseases. With a strong focus on neuroscience and cancer, Bionomics has built a diverse pipeline of potential treatments. The company has a rich history of collaboration with pharmaceutical giants, such as Merck & Co. and Ironwood Pharmaceuticals, which further strengthens its research capabilities. Bionomics is known for its expertise in discovering novel drug targets and utilizing its proprietary drug discovery platform, known as MultiCore. Over the years, Bionomics has cultivated a reputation for delivering cutting-edge solutions in the field of biotechnology.

Bionomics Ltd has achieved several significant milestones. The company successfully developed BNC105, a promising anti-cancer drug candidate. In addition, Bionomics has entered into strategic partnerships and collaborations with notable pharmaceutical companies including Merck & Co. and Ironwood Pharmaceuticals. These partnerships have paved the way for the advancement of their drug pipeline. Furthermore, Bionomics has made progress in clinical trials, demonstrating positive results in various studies. With a strong focus on innovation and research, Bionomics Ltd continues to make strides in the pharmaceutical industry, driving potential growth and success.

Bionomics Ltd is primarily present in two countries, Australia and the United States. The company is headquartered in Adelaide, South Australia, and has research and development facilities in San Diego, California. With a focus on developing innovative therapeutics for various diseases, Bionomics Ltd has established a strong presence in these regions. The company's presence in these countries allows it to leverage the scientific and business expertise available in both Australia and the United States, contributing to its mission of discovering and advancing novel drugs.

Bionomics Ltd is a biotechnology company that represents core values of innovation, scientific excellence, and dedication to improving healthcare outcomes. With a strong corporate philosophy, Bionomics strives to create novel and differentiated therapeutics to address unmet medical needs. Their commitment to cutting-edge research and development is evident in their focus on discovering and advancing drug candidates in areas like cancer, central nervous system disorders, and inflammatory diseases. Bionomics Ltd aims to deliver value to patients, healthcare providers, and investors through their robust pipeline and strategic collaborations. As a leading biotech firm, Bionomics maintains a steadfast commitment to improving lives through pioneering scientific advancements.

6 analyytikkoa arvioi tällä hetkellä Bionomics-osaketta: 4 suosittaa ostoa, 2 pitoa ja 0 myyntiä.

Bionomics Analyytikkojen kursstavoitteet 2026

Bionomics-osake (BNO.AX) on listattuna 4 pörssissä, muun muassa: ASX (BNO.AX), Frankfurt (B1N.F), München (B1N.MU), Düsseldorf (B1N.DU).

The Australian company Bionomics Ltd is a biopharmaceutical company that was founded in 1998 and is headquartered in Adelaide. The company specializes in researching, developing, and marketing innovative therapies for neurological disorders, cancer, and metabolic diseases. Bionomics Ltd's business model includes two main divisions: the development of its own drugs and therapies, and collaboration with other pharmaceutical companies for joint drug development. One core competency of Bionomics Ltd is the research of peptide-based drugs. These drugs are derived from proteins and can be specifically used in the body to target certain cells or receptors. The company has filed several patents for peptide-based drugs and is currently developing promising drug candidates for cancer, depression, and anxiety disorders. Additionally, Bionomics Ltd has a strong expertise in drug research through the use of artificial intelligence (AI) and machine learning. The company uses these technologies to identify new drugs that target specific structures in the body, enabling more targeted and effective drug development. Bionomics Ltd also collaborates with other companies in the industry to facilitate the exchange of resources and expertise. The company has partnerships with various pharmaceutical companies and academic institutions to develop drugs together. This collaboration allows for a broader range of drugs and increased effectiveness, while also reducing development costs. Bionomics Ltd offers both its own drugs and drugs developed in collaboration with other companies. One promising product is the drug candidate "BNC210", which is being developed for the treatment of anxiety disorders. The drug has shown high efficacy and precision, making it a promising candidate in the market. Another promising product is "BNC101", a drug candidate for certain types of cancer that is currently being tested in Phase 2 studies. Overall, Bionomics Ltd has a flexible and diversified business model that allows the company to develop its own products and work with other companies. With its expertise in peptide-based drug research and the use of AI, the company is gaining importance in the industry. The portfolio of products and projects that the company is currently developing and bringing to market shows promising progress and makes Bionomics Ltd a company that will be successful in the long run.

Liikevaihtoa ei voida laskea Bionomics:lle tällä hetkellä.

Voittoa ei voida laskea Bionomics:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Bionomics:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Bionomics:lle tällä hetkellä.

Bionomics:n Eulpool-laatuscore on 3/10.

Bionomics:n ISIN on AU000000BNO5. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Bionomics:n WKN on 936199. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Bionomics:n ticker on BNO.AX. Tämä pörssinoteeraus käytetään Bionomics-osakkeiden kauppaan pörssissä.